Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCND1 | P24385 | 2/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11045503 | 1.00 | NFE2L2 (0.53) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL30569765 | 1.00 | NFE2L2 (0.53) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL12651352 | 0.83 | XDH (0.50) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL22417964 | 0.82 | XDH (0.48) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL18255202 | 0.82 | XDH (0.48) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL31335285 | 0.82 | XDH (0.48) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL18345531 | 0.82 | XDH (0.48) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL21676224 | 0.82 | XDH (0.48) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL21676111 | 0.82 | VCP (0.57) | NFE2L2XDHALDH1A1KDM4EMAPT | |
| SCHEMBL14990172 | 0.82 | XDH (0.48) | NFE2L2XDHALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106496178-A | A kind of ticagrelor midbody and preparation method thereof | 青岛辰达生物科技有限公司 | 2017-03-15 | — | — | CN | claimed |
| CN-116693551-A | Dihydropyrazole azepine compound, pharmaceutical composition containing same and application of compound in resisting tumor | 浙江大学 | 2023-09-05 | — | — | CN | disclosed |
| US-11319300-B2 | Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof | GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| CN-105576138-B | Platinum (II) isoquinoline-pyridine-benzene-based complex, preparation method thereof and organic light emitting diode prepared therefrom | 港大科桥有限公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-3124486-B1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OF ANTITUMOR THEREOF | UNIV ZHEJIANG (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-20200165229-A1 | POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF | GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| CN-108341801-B | Polyfluoro-substituted aromatic heterocycle derivatives, pharmaceutical composition containing polyfluoro-substituted aromatic heterocycle derivatives and application of polyfluoro-substituted aromatic heterocycle derivatives | 浙江大学 | 2020-05-12 | — | — | CN | disclosed |
| US-10233180-B2 | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof | ZHEJIANG UNIVERSITY (CN) | 2019-03-19 | — | — | US | disclosed |
| US-20170107213-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF | ZHEJIANG UNIVERSITY (CN) | 2017-04-20 | — | — | US | disclosed |
| CN-106496178-A | A kind of ticagrelor midbody and preparation method thereof | 青岛辰达生物科技有限公司 | 2017-03-15 | — | — | CN | disclosed |
| EP-3124486-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OF ANTITUMOR THEREOF | Zhejiang University (CN) | 2017-02-01 | — | — | EP | disclosed |
| EP-2739626-B1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INT BV (NL) | 2016-05-04 | — | — | EP | disclosed |
| US-9096599-B2 | Spiroindoline compounds | INTERVET INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140163056-A1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INC. | 2014-06-12 | — | — | US | disclosed |
| EP-2739626-A1 | NOVEL SPIROINDOLINE COMPOUNDS | Intervet International B.V. (NL) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013017678-A1 | NOVEL SPIROINDOLINE COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2013-02-07 | — | — | WO | disclosed |
| EP-2443132-A1 | PLATINUM (II) ISOQUINOLINE-PYRIDINE-BENZENE BASED COMPLEXES, PREPARING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DIODES MADE THEREFROM | Versitech Limited (CN) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010145190-A1 | PLATINUM (II) ISOQUINOLINE-PYRIDINE-BENZENE BASED COMPLEXES, PREPARING METHOD THEREOF, AND ORGANIC LIGHT-EMITTING DIODES MADE THEREFROM | THE UNIVERSITY OF HONG KONG (CN) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010144293-A1 | SYNTHESIS OF TELCAGEPANT AND INTERMEDIATES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165229-A1 | POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF | BPHL, AR, FRK | NFE2L2 1363/4885XDH 1551/4885ALDH1A1 2527/4885 |
| US-20170107213-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF | AKT1, RELA, AKT3 | NFE2L2 362/4885XDH 1597/4885ALDH1A1 4209/4885 |
| US-11319300-B2 | Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof | AKT1, AKT2, AKT3 | NFE2L2 1658/4885XDH 2803/4885ALDH1A1 3227/4885 |
| US-10233180-B2 | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof | AKT1, AKT3, RELA | NFE2L2 440/4885XDH 1291/4885ALDH1A1 4086/4885 |
| US-20140163056-A1 | NOVEL SPIROINDOLINE COMPOUNDS | PKD2, PKD1, REN | NFE2L2 1186/4885XDH 1446/4885ALDH1A1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.